Lyon, Timothy D <br/><br/>
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era.  [electronic resource] 

 -  Urologic oncology  11 2018 
 - 499.e1-499.e7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1873-2496 
<br/><br/><label>Standard No.: </label>10.1016/j.urolonc.2018.08.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Cohort Studies<br/>Combined Modality Therapy--methods<br/>Cytoreduction Surgical Procedures<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Immunotherapy--methods<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy--methods<br/>Nephrectomy--methods<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Risk Factors<br/>Sorafenib--therapeutic use